- Home
- ADPT vs DAVE Comparison
ADPT vs DAVE Comparison
Compare ADPT & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | DAVE |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADPT | DAVE |
|---|---|---|
| Price | $14.08 | $273.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $17.78 | ★ $312.75 |
| AVG Volume (30 Days) | ★ 1.8M | 554.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | $26.28 |
| Revenue Next Year | $22.72 | $17.38 |
| P/E Ratio | ★ N/A | $17.85 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $7.16 | $88.58 |
| 52 Week High | $20.76 | $287.69 |
Technical Indicators
Market Signals| Indicator | ADPT | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 75.95 |
| Support Level | $12.22 | $181.96 |
| Resistance Level | $17.52 | N/A |
| Average True Range (ATR) | 0.84 | 13.90 |
| MACD | 0.06 | 9.08 |
| Stochastic Oscillator | 54.11 | 89.06 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.